Precision management of cervical cancer - Review - emphasizes immunotherapy combination regimens and translational advances

Sep 23, 2026

Cervical cancer remains a major global health burden, especially where screening and human papillomavirus (HPV) vaccination access is limited. Early-stage surgery and chemoradiation can cure many patients, yet persistent, recurrent, and metastatic disease outcomes remain poor, driving demand for more effective individualized systemic therapies. This review defines precision management as biomarker-and microenvironment-informed selection of immunotherapy-based regimens and rational combination design to overcome resistance. The authors synthesize cervical cancer immune biology, compare key positive and negative trials to explain differential efficacy, and discuss translational enablers such as biomarkers, delivery platforms, and organoid models to accelerate evidence-based personalization.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages13

Reading Time33 min

AccessFree to download

Abstract

1 Introduction

2 Current treatments for cervical cancer

Prognosis and treatment selection by stage

Shi et al. Discover Oncology (2026) 17:435 [https://doi.org/10.1007/s12672-026-04588-y](https://doi.org/10.1007/s12672-026-04588-y) Discover Oncology REVIEW Open Access Precision management of cervical cancer emphasizes immunotherapy combination regimens and translational advances Huan Shi1, Xinyun Huang4, Jie Yu1, Weiyan Shan1, Jingxia Zhang1, Qiaoping Xu3*† and Hongkai Shang2*† †Qiaoping Xu and Hongkai Shang contributed equally to this work. *Correspondence: Qiaoping Xu [xqp1984@126.com](xqp1984@126.com)[ ](xqp1984@126.com)Hongkai Shang [15990032799@aliyun.com](15990032799@aliyun.com) Full list of author information is available at the end of the article Abstract Cervical cancer remains a major global health burden, particularly in settings with limited access to screening and human papillomavirus (HPV) vaccination. Although surgery and chemoradiation can achieve high cure rates in early-stage disease, outcomes for persistent, recurrent, or metastatic disease remain poor, highlighting the need for more effective and individualized systemic therapies. Immune checkpoint inhibitors have become integral to the treatment landscape, yet clinical benefit is modest for many patients and biomarker guidance remains imperfect. In this review, we define “precision management” as the biomarker-and microenvironment-informed selection of immunotherapy-based regimens across disease settings, coupled with rational combination design to overcome resistance. We synthesize cervical cancer–specific immune biology, including HPV-mediated immune evasion, and critically compare pivotal positive and negative clinical trials to explain why certain combinations succeed or fail. Finally, we discuss translational enablers—robust biomarkers, optimized delivery platforms, and functional models such as organoids—that may accelerate evidence-based personalization of immunotherapy in cervical cancer. Keywords Cervical cancer, Immune checkpoint inhibition, Immunotherapy, PD-1, CTLA-4 1 Introduction Cervical cancer (CC) comprises predominantly squamous cell carcinoma and adenocarcinoma, with less common epithelial and neuroendocrine subtypes. Globally, CC remains the fourth most commonly diagnosed cancer and a leading cause of cancerrelated mortality in women, with an estimated 660,000 new cases and approximately 350,000 deaths in 2022 [1]. Persistent infection with high-risk human papillomavirus (hrHPV), especially HPV16/18, is the principal carcinogenic driver. Viral oncoproteins E6 and E7 promote malignant transformation through disruption of p53 and retinoblastoma (pRB) pathways, while progression to invasive disease typically requires failure of © The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-nd/4.0/. Shi et al. Discover Oncology (2026) 17:435 Page 2 of 13 immune control and acquisition of additional host and environmental risk factors (e.g., smoking, immunosuppression, parity, and limited access to screening) [2, 3]. D

FAQs

Why is cervical cancer called a major global health burden in this review?

The review states cervical cancer remains a leading cause of cancer-related mortality in women, particularly in settings with limited screening and HPV vaccination access. It emphasizes the high numbers of new cases and deaths globally and the ongoing poor outcomes for advanced disease.

How does the review define “precision management” for cervical cancer?

“Precision management” is defined as selecting immunotherapy-based regimens using biomarkers and the tumor microenvironment, tailored across disease settings. It also includes rational combination design intended to overcome immunotherapy resistance.

What immune-related factors limit responses to immune checkpoint inhibitors?

The review highlights immune evasion through impaired antigen presentation, suppressed interferon (IFN) signaling, and a tumor microenvironment skewed toward myeloid and regulatory T cells. These mechanisms contribute to heterogeneous and often limited responses to ICIs.

Sep 23, 2026

Uploaded by Valentina